Hancock Jaffe is UNDERVALUED at 14.54 per share with modest projections ahead. We consider Hancock Jaffe slightly risky.
Hancock Jaffe Labora holds Efficiency (Sharpe) Ratio of 0.0243, which attests that the entity had 0.0243% of return per unit of risk over the last month. Our standpoint towards determining the volatility of a stock is to use all available market data together with stock specific
technical indicators that cannot be
diversified away. We have found twenty-seven
technical indicators for Hancock Jaffe Labora, which you can use to evaluate future volatility of the firm. Please check out Hancock Jaffe Downside Deviation of 4.2,
market risk adjusted performance of 0.239, and Risk Adjusted Performance of 0.0365 to validate if the risk estimate we provide is consistent with the expected return of 0.16%.
How important is Hancock Jaffe's Liquidity
Hancock Jaffe
financial leverage refers to using borrowed capital as a funding source to finance Hancock Jaffe Laboratories ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Hancock Jaffe financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Hancock Jaffe's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Hancock Jaffe's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Hancock Jaffe's total debt and its cash.
An Additional Perspective On Hancock Jaffe Labora
The modest gains experienced by current holders of Hancock Jaffe Laboratories may raise some interest from stockholders. The stock closed today at a share price of
11.54 on
19,595,600 in trading volume. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in
November. The stock standard deviation of daily returns for 30 days investing horizon is currently 6.62. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Hancock Jaffe Laboratories partners.
Asset Utilization
One of the ways to look at asset utilization of Hancock is to check how much profit was generated for every dollar of assets it reports. Hancock Jaffe retains a negative application of resources of -65.33 (percent), losing $0.65 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Hancock Jaffe Laboratories shows how discouraging it operates for each dollar spent on its resources.
| Current Assets1.4 M | Assets Non Current2 M | |
| Current Assets | 1.45 Million | 35.0 |
| Assets Non Current | 1.95 Million | 47.16 |
| Goodwill | 737,954 | 17.84 |
Our perspective of the current Hancock Jaffe rise
The skewness is down to 3.87 as of today. As of the 12th of December 2020, Hancock Jaffe retains the Risk Adjusted Performance of 0.0365,
downside deviation of 4.2, and Market Risk Adjusted Performance of 0.239. Hancock Jaffe
technical analysis makes it possible for you to employ
historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down and interpolate data for nineteen
technical drivers for Hancock Jaffe Labora, which can be compared to its competitors. Please check out
Hancock Jaffe Labora jensen alpha, as well as the
relationship between the potential upside and
skewness to decide if Hancock Jaffe is priced fairly, providing market reflects its last-minute price of 11.54 per share. Given that Hancock Jaffe Laboratories has
jensen alpha of 0.0766, we strongly advise you to confirm Hancock Jaffe Labora's regular market performance to make sure the company can sustain itself at a future point.
The Current Takeaway on Hancock Jaffe Investment
While some firms under the medical devices industry are still a bit expensive, Hancock Jaffe may offer a potential longer-term growth to stockholders. To conclude, as of the 12th of December 2020, we believe that Hancock Jaffe is currently
undervalued with
very high chance of distress in the next two years. However, our present 30 days buy-sell recommendation on the company is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Hancock Jaffe Laboratories. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
